Monday, July 15, 2024

AstraZeneca launches Evinova, a health technology company to accelerate life sciences innovation, clinical trial delivery and better health outcomes

Related stories

Synchron Announces Brain Computer Interface Chat Feature Powered by OpenAI

New feature includes AI-driven emotion and language predictions for...

Inspiro Wins Multiple Gold Honors from Globee® Awards

Inspiro, a leading global CX outsourcing company, is excited...

Peak Boosts Business Productivity with General Release of Agentic AI Assistant, Co:Driver

Artificial intelligence company Peak announced the general availability of Co:Driver,...

Evinova’s globally scaled digital healthcare solutions are evidence-based, science-based and human-experience-based, serving clinical trial sponsors, clinical research organizations (CROs), clinical trial site care teams and patients.

AstraZeneca launched Evinova, which aims to become a leading provider of digital healthcare solutions to better meet the needs of healthcare professionals, regulators and patients. With the long-standing support of AstraZeneca and strategic partnerships with Parexel and Fortrea, Evinova provides globally scaled digital products and services to the life sciences and healthcare industries.

Evinova will prioritize bringing to market established and scaled digital technology solutions already used globally by AstraZeneca to optimize the design and execution of clinical trials. This will reduce the time and costs of developing new medicines, bring care closer to home for patients and reduce pressure on healthcare systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas.

Building on AstraZeneca’s deep experience developing new therapies and drawing on insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions for pharmaceuticals, biotechs and CROs to support clinical research worldwide. The technologies have already been used in the successful conduct of multiple AstraZeneca-sponsored clinical trials in more than 40 countries.

Also Read: TraceLink Secures Merit Award for Healthcare Innovation with AI-Powered Product Availability Intelligence Solution

Pascal Soriot, Chief Executive Officer of AstraZeneca, stated: “ The future of drug development can be accelerated with digital solutions. We believe that Evinova’s combination of scientific expertise and track record in developing AI-based digital technologies at scale offers a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions. Reduce.”

Cristina Duran, President of Evinova, said: “ We are excited to offer the portfolio of globally scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the broader life sciences community. We believe this will drive the industry forward in digital healthcare, as we know healthcare professionals and regulators need digital solutions that work across the pharmaceutical sector and support patients broadly. Evinova, with industry roots and proven experience, will be uniquely positioned to deliver science, evidence and human experience-based solutions with the aim of improving patient experience and outcomes.”

Globally leading CROs Parexel and Fortrea have entered into agreements to offer Evinova’s digital healthcare solutions to their broad customer base. To accelerate industry adoption and maintain and expand the global reach of its digital products, Evinova is partnering with Accenture and Amazon Web Services.

Evinova will combine the clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology, including strategy and development, digital product development, data science and AI, user experience design and behavioral sciences. In addition to digital solutions, Evinova will offer customized scientific solutions, including remote patient monitoring and novel endpoint solutions, as well as study design and advisory services.

SOURCE: BusinessWire


- Never miss a story with notifications

    Latest stories